WebDoctor Encyclopedia

Childhood Soft-tissue sarcomas

Desmoplastic small round cell tumour (DSRCT)

Desmoplastic small round cell tumour (DSRCT) is a very rare, aggressive sarcoma that grows on the lining of the abdomen, mostly in teenage boys and young men. It carries an EWSR1-WT1 gene fusion.

Medically reviewed Last reviewed October 17, 2026

What is desmoplastic small round cell tumour?

Desmoplastic small round cell tumour (DSRCT) is a very rare and aggressive cancer that usually grows on the lining of the abdomen and pelvis (the peritoneum). It belongs to the group of cancers called soft-tissue sarcomas.

It mainly affects teenage boys and young men. About 85-90% of patients are male, and most are between 10 and 30 years old.

The name describes how the tumour looks under the microscope. Small round cells grow in nests surrounded by dense, scar-like fibrous tissue, which pathologists call desmoplastic stroma.

DSRCT was first described in 1989. It is caused by a specific gene change in the tumour cells, a fusion between the EWSR1 and WT1 genes, which confirms the diagnosis (Gerald et al., 1998).

DSRCT usually forms many tumour nodules scattered over the peritoneum rather than a single lump. In most people it has already spread within the abdomen, and often to the liver, by the time it is found.

Treatment is intensive and combines chemotherapy, major surgery and radiotherapy. It is best delivered at a specialist sarcoma centre.

1. Key facts at a glance

Feature Details
Type of cancer Soft-tissue sarcoma of the small round cell family
How common Very rare; a few hundred cases are reported worldwide each year
Typical age Mostly 10-30; median about 20-22
Sex About 85-90% male
Main site Lining of the abdomen and pelvis, usually with many nodules
Gene change EWSR1::WT1 fusion, from the chromosome change t(11;22)(p13;q12)
Spread Peritoneum, liver, lymph nodes, lungs and bone
Main treatments Intensive chemotherapy, cytoreductive surgery, whole-abdomen radiotherapy
Outlook About 15-25% alive at 5 years

2. Causes and risk factors

The cause of DSRCT is not known. There are no known lifestyle or environmental risk factors, and it is not inherited.

All DSRCTs carry the same gene change. Part of the EWSR1 gene on chromosome 22 joins with part of the WT1 gene on chromosome 11.

This creates an abnormal protein that switches on genes driving cell growth (Gerald and Haber, 2005). The change happens only in the tumour cells and is not passed on to children.

Feature What is known
Sex Strongly male; the reason is unknown
Age Adolescents and young adults
Ethnicity No clear pattern
Family history Not linked
Previous illness or exposures No known link

DSRCT outside the abdomen

In a small number of people, DSRCT starts outside the abdomen. Reported sites include the pleura (lining of the lungs), the area around the testis, the kidney, bone, soft tissues of the limbs, and the head and neck.

These tumours carry the same EWSR1::WT1 fusion and are treated in the same way. Because they are so unusual, gene testing is especially important to reach the correct diagnosis.

3. How does it look

Inside the abdomen

At surgery or on scans, DSRCT typically appears as one large mass together with many smaller nodules. The nodules may number from a few to hundreds and are spread over the peritoneum.

The largest mass is often in the pelvis, behind the bladder, or in the area around the bowel. The nodules are firm, white-grey and gritty because of the dense fibrous tissue.

Fluid in the abdomen (ascites) is common. The tumour often involves the omentum, the fatty apron of tissue hanging from the stomach.

On scans

Scan What doctors may see
CT of chest, abdomen and pelvis Multiple soft-tissue masses in the abdomen and pelvis without an obvious organ of origin; may show liver deposits and enlarged lymph nodes
MRI Helps map pelvic and liver disease
PET-CT Shows active tumour sites and is useful for staging and checking response

Under the microscope

The pathologist sees nests of small, round blue cells in thick fibrous tissue.

DSRCT cells show an unusual mix of features from several cell types:

Marker Typical result
Cytokeratin and EMA Positive (epithelial features)
Desmin Positive, often in a dot-like pattern (muscle features)
Neuron-specific enolase, CD56 Often positive (nerve features)
WT1 (C-terminal) Positive in the nuclei
EWSR1::WT1 fusion Confirmed by FISH, RT-PCR or sequencing

The gene test is important because DSRCT can be confused with Ewing sarcoma, rhabdomyosarcoma, lymphoma and neuroblastoma.

Visible signs on the body

There may be no outward signs early on. As the disease grows, the abdomen may swell noticeably, and a lump may be felt. Weight loss may make the arms and face look thinner while the abdomen enlarges.

4. Symptoms

DSRCT often grows silently for a long time because the abdomen has plenty of space. Symptoms tend to be vague, and many young men are first thought to have a minor stomach problem.

Common symptoms

  • Abdominal pain or discomfort, often vague and gradually worsening
  • Swelling of the abdomen, from tumour or fluid
  • A lump that can be felt in the abdomen or pelvis
  • Feeling full quickly, nausea or loss of appetite
  • Constipation or, occasionally, symptoms of bowel blockage, such as vomiting and severe cramping
  • Needing to pass urine often or difficulty passing urine, from pressure on the bladder
  • Weight loss and tiredness
  • Back or pelvic pain
  • Swelling of the scrotum in some men, as the peritoneum extends there
  • Breathlessness if fluid collects around the lungs or the tumour spreads to the lungs

When to see a doctor

See a doctor about abdominal pain or swelling that does not settle, particularly if it comes with weight loss or a lump. Young men with these symptoms should not be dismissed as having a simple digestive problem if symptoms persist for more than a few weeks.

5. Diagnosis

Test Purpose
Physical examination Feels for lumps, swelling or fluid
Blood tests General health, kidney and liver function; tumour markers such as CA125 and NSE may be raised but are not specific
CT scan Main scan for finding the extent of disease
MRI Better detail of the pelvis and liver
PET-CT Finds disease outside the abdomen and helps with staging
Biopsy Needle biopsy, laparoscopy or surgery to obtain tissue
Molecular testing Confirms the EWSR1::WT1 fusion
Bone marrow and bone scans Sometimes done if spread is suspected

6. Spread of the disease

There is no specific staging system for DSRCT. Doctors describe the disease by how much is in the abdomen and whether it has spread outside.

Extent Description
Peritoneal only Disease limited to the lining of the abdomen and pelvis
Liver involvement Deposits on or in the liver; seen in about half of patients
Lymph nodes Abdominal, pelvic and sometimes chest lymph nodes
Outside the abdomen Lungs, bone, pleura (lining of the lungs) or bone marrow

The peritoneal cancer index (PCI) is often used at surgery to score how much of the abdomen is involved.

7. Treatment

Treatment combines several approaches and lasts many months. It should be planned by a specialist sarcoma team with experience of DSRCT.

Chemotherapy

Chemotherapy is the first treatment for almost everyone. Intensive regimens similar to those used for Ewing sarcoma are used.

Regimen Drugs
P6 protocol High-dose cyclophosphamide, doxorubicin and vincristine, alternating with ifosfamide and etoposide (Kushner et al., 1996)
Ewing-type regimens Vincristine, doxorubicin and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE)

Usually about 4-7 cycles are given before surgery to shrink the tumours.

Surgery

If chemotherapy shrinks the disease enough, the surgeon aims to remove all visible tumour, known as complete cytoreductive surgery. This can be a long operation that removes hundreds of nodules and sometimes parts of organs.

Studies show that people who have complete removal of their tumours after chemotherapy live longer than those who do not (Lal et al., 2005; Subbiah et al., 2018).

HIPEC

Hyperthermic intraperitoneal chemotherapy (HIPEC) means bathing the abdomen with heated chemotherapy, usually cisplatin, at the end of surgery. It aims to kill microscopic disease.

It has been studied in DSRCT with mixed results (Hayes-Jordan et al., 2018). It is offered in some centres and clinical trials, but it is not standard everywhere.

Radiotherapy

Whole abdominopelvic radiotherapy (WAP-RT) treats the entire abdomen and pelvis after surgery. It can lower the risk of the cancer returning in the abdomen.

It can cause bowel and blood count side effects. Radiotherapy can also relieve pain from specific tumour sites.

Treatment when the disease comes back

Option Notes
Further chemotherapy Irinotecan with temozolomide, high-dose ifosfamide, cyclophosphamide with topotecan
Targeted drugs Pazopanib or other tyrosine kinase inhibitors may slow the disease
Trabectedin Used for some relapsed sarcomas
Clinical trials New antibodies, radio-labelled treatments and drugs targeting the fusion protein
Palliative care Pain control, drainage of fluid and nutrition support

Side effects of treatment

Because treatment is so intensive, side effects are common. Most are temporary, but some can be long-lasting.

Treatment Common side effects Possible long-term effects
Chemotherapy Low blood counts and infections, sickness, hair loss, mouth sores, tiredness Reduced fertility, heart effects from doxorubicin, kidney effects from ifosfamide, small risk of a second cancer
Cytoreductive surgery Pain, slow return of bowel function, wound problems Bowel adhesions and blockages, digestive changes
HIPEC Kidney strain from cisplatin, longer recovery Hearing loss from cisplatin
Whole-abdomen radiotherapy Diarrhoea, nausea, low blood counts Bowel narrowing, liver and kidney effects, reduced fertility

Follow-up

After treatment, scans such as CT or PET-CT are usually done every 2-3 months for the first two years, as most relapses happen in this period. The interval then gradually lengthens.

Long-term survivors also need check-ups for the late effects of treatment, including heart, kidney, hearing and hormone tests.

8. Outlook (prognosis)

DSRCT is one of the most difficult sarcomas to treat. Most patients respond to the first chemotherapy, but the cancer often comes back.

Factor Effect on outlook
Complete cytoreductive surgery Linked with longer survival
Response to chemotherapy Good response improves the chance of surgery and survival
Spread outside the abdomen Poorer outlook
Liver involvement Generally poorer outlook
Combined treatment (chemotherapy, surgery and radiotherapy) Best results in published series

Overall, about 15-25% of patients are alive 5 years after diagnosis. A small number of people achieve long-term remission after intensive combined treatment (Subbiah et al., 2018).

9. Living with DSRCT

DSRCT and its treatment affect every part of a young person’s life, including education, work, relationships and fertility.

Need What helps
Fertility Sperm or egg storage before chemotherapy should be offered
Nutrition Dietitian support; some patients need feeding through a tube or vein
Pain and bowel symptoms Specialist pain and symptom control
Emotional support Teenage and young adult cancer services, psychologists and peer support groups
Education and work Support to stay in contact with school, university or work
Clinical trials Ask about trials, which may offer access to new treatments

10. Frequently asked questions

Question Answer
Is DSRCT inherited? No. The gene fusion occurs only in the tumour cells
Why does it mainly affect young men? The reason is not known
Can it be cured? Some people achieve long-term remission with intensive treatment, but the risk of relapse is high
Why is surgery done after chemotherapy? Shrinking the tumours first makes complete removal more likely
Is DSRCT the same as Ewing sarcoma? No. They share the EWSR1 gene, but the partner gene and behaviour are different

11. Questions to ask your care team

  • Has the diagnosis been confirmed by molecular testing?
  • Has the disease spread outside the abdomen?
  • Which chemotherapy regimen do you recommend?
  • Will I be able to have cytoreductive surgery, and is HIPEC an option?
  • Will I need whole-abdomen radiotherapy?
  • Are there clinical trials I could join?
  • How can I preserve my fertility?

Resources

  1. Gerald, W.L. et al. (1998) ‘Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants’, Journal of Clinical Oncology, 16(9), pp. 3028-3036.
  2. Gerald, W.L. and Haber, D.A. (2005) ‘The EWS-WT1 gene fusion in desmoplastic small round cell tumor’, Seminars in Cancer Biology, 15(3), pp. 197-205.
  3. Kushner, B.H. et al. (1996) ‘Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy’, Journal of Clinical Oncology, 14(5), pp. 1526-1531.
  4. Lal, D.R. et al. (2005) ‘Results of multimodal treatment for desmoplastic small round cell tumors’, Journal of Pediatric Surgery, 40(1), pp. 251-255.
  5. Subbiah, V. et al. (2018) ‘Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival’, Clinical Cancer Research, 24(19), pp. 4865-4873.
  6. Hayes-Jordan, A.A. et al. (2018) ‘Desmoplastic small round cell tumor treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results of a phase 2 trial’, Annals of Surgical Oncology, 25(4), pp. 872-877.
  7. Bulbul, A. et al. (2017) ‘Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations’, Sarcoma, 2017, p. 1278268.
  8. WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  9. National Cancer Institute (2026) Childhood Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.